cytidine has been researched along with 4'-azidocytidine in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (66.67) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cammack, N; Devos, R; Granycome, C; Hang, JQ; Heindl, D; Hobbs, CJ; Jiang, WR; Kang, H; Klumpp, K; Laxton, C; Le Pogam, S; Lévêque, V; Ma, H; Martin, JA; Merrett, JH; Nájera, I; Sarma, K; Singer, M; Smith, DB; Symons, J | 1 |
| Ali, S; Cammack, N; Jiang, S; Jiang, WR; Kang, H; Klumpp, K; Le Pogam, S; Leveque, V; Ma, H; Nájera, I; Rajyaguru, S; Singer, M; Smith, D; Symons, J | 1 |
| Baker, SJ; Blomgren, PA; Cammack, N; Devos, R; Granycome, C; Hang, J; Hobbs, CJ; Jiang, WR; Klumpp, K; Laxton, C; Le Pogam, S; Leveque, V; Ma, H; Maile, G; Martin, JA; Merrett, JH; Najera, I; Pichota, A; Sarma, K; Smith, DB; Smith, M; Swallow, S; Symons, J; Vesey, D | 1 |
| Sulkowski, MS | 1 |
| Ali, S; Cammack, N; Jiang, WR; Kang, H; Le Pogam, S; McCown, MF; Najera, I; Rajyaguru, S; Symons, J | 1 |
| Cammack, N; Chiu, S; Hu, S; Kang, H; Kosaka, A; Le Pogam, S; Nájera, I; Rajyaguru, S; Seshaadri, A; Symons, J | 1 |
| Berns, H; Cooksley, G; Dore, GJ; Hill, G; Klumpp, K; Najera, I; Roberts, SK; Robson, R; Shaw, D; Washington, C | 1 |
| Chan, A; Everson, GT; Fried, MW; Ghalib, R; Godofsky, E; Harrison, S; Hill, G; Najera, I; Nelson, D; Nyberg, L; Pockros, PJ; Rodriguez-Torres, M; Shiffman, ML | 1 |
| Alfredson, T; Birudaraj, R; Brandl, M; Hadig, X; Hill, G; Holper, M; Hong, L; Jia, Z; Larrabee, S; Reddy, M; Sarma, K; Smith, DB; Tran, T; Washington, C; Wu, X | 1 |
| Ali, S; Alker, A; Cammack, N; Inocencio, N; Jiang, WR; Kang, H; Klumpp, K; Le Pogam, S; Leveque, V; Ma, H; Najera, I; Philipp, F; Smith, M; Symons, J | 1 |
| Kronenberger, B; Zeuzem, S | 1 |
| Daverio, F; Kelleher, MR; Klumpp, K; Le Pogam, S; Luoni, G; Martin, JA; McGuigan, C; Mulready, S; Najera, I; Perrone, P; Rajyaguru, S; Smith, DB | 1 |
| Alfredson, T; Brandl, M; Hadig, X; Hong, L; Huang, S; Li, F; Tran, T; Wu, X | 1 |
| Abdul Ghafar, N; Blasco, F; Cerny, D; Chen, YL; Fink, K; Fu, Y; Gu, F; Herve, M; Karuna, R; Lim, SP; Schul, W; Shi, PY; Wang, G; Yokohama, F | 1 |
| Chang, J; Chen, X; Cheng, T; Dong, L; Guo, M; Guo, X; Jiang, J; Peng, Y; Wang, Q; Zhang, J; Zhang, Y | 1 |
| Behera, I; Beigelman, L; Chaudhuri, S; Deval, J; Dyatkina, N; Jekle, A; Jin, Z; Kinkade, A; Rajwanshi, VK; Smith, DB; Symons, JA; Tucker, K; Wang, G | 1 |
| He, B; Hotard, AL; Lo, MK; Nichol, ST; Spiropoulou, CF | 1 |
| Deval, J; Jordan, PC; Lo, MK; Nichol, ST; Spiropoulou, CF; Stevens, S; Tam, Y | 1 |
2 review(s) available for cytidine and 4'-azidocytidine
| Article | Year |
|---|---|
Specific targeted antiviral therapy for hepatitis C.
Topics: Antiviral Agents; Benzofurans; Clinical Trials as Topic; Cytidine; Hepatitis C; Humans; Prodrugs; Proline; Protease Inhibitors; RNA-Dependent RNA Polymerase | 2007 |
Future treatment options for HCV: double, triple, what is the optimal combination?
Topics: Antiviral Agents; Cytidine; DNA-Directed RNA Polymerases; Drug Delivery Systems; Drug Resistance, Viral; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Oligopeptides; Polyethylene Glycols; Prodrugs; Proline; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin | 2008 |
2 trial(s) available for cytidine and 4'-azidocytidine
| Article | Year |
|---|---|
Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cytidine; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Nucleosides; Prodrugs; RNA, Viral; Single-Blind Method; Time Factors; Viral Load | 2008 |
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Female; Hepacivirus; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Nucleosides; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
14 other study(ies) available for cytidine and 4'-azidocytidine
| Article | Year |
|---|---|
The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture.
Topics: Antiviral Agents; Cell Line; Cytidine; Hepacivirus; Humans; RNA-Dependent RNA Polymerase; RNA, Viral; Viral Nonstructural Proteins; Virus Replication | 2006 |
In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.
Topics: Antiviral Agents; Cell Line; Cytidine; Drug Resistance, Viral; Genome, Viral; Hepacivirus; Humans; Interferon-alpha; Molecular Structure; RNA, Viral; Virus Replication | 2006 |
Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Cytidine; Drug Design; Drug Evaluation, Preclinical; Hepacivirus; Inhibitory Concentration 50; Models, Chemical; Molecular Conformation; Nucleosides; Ribonucleosides; RNA; Uridine; Virus Replication | 2007 |
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
Topics: Antiviral Agents; Cytidine; Deoxycytidine; Drug Resistance, Viral; Hepacivirus; Nucleosides; Oligopeptides; Protease Inhibitors; Replicon; Serine Endopeptidases; Viral Nonstructural Proteins; Virus Replication | 2008 |
Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Cytidine; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Mutation, Missense; Pyrimidine Nucleosides; Sequence Analysis, DNA; Viral Nonstructural Proteins; Virus Replication | 2008 |
Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability.
Topics: Antiviral Agents; Biological Availability; Caco-2 Cells; Cytidine; DNA-Directed RNA Polymerases; Dose-Response Relationship, Drug; Drug Stability; Hepacivirus; Humans; Hydrolysis; Nucleosides; Particle Size; Permeability; Prodrugs; Solubility; Viral Nonstructural Proteins | 2008 |
Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Topics: Antiviral Agents; Cell Line; Cytidine; Deoxycytidine; Drug Resistance, Viral; Genetic Variation; Hepacivirus; Humans; Molecular Sequence Data; Replicon; RNA-Dependent RNA Polymerase; Sequence Analysis, DNA; Viral Nonstructural Proteins | 2008 |
The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4'-azidocytidine (R1479).
Topics: Amino Acids; Antiviral Agents; Chemistry, Pharmaceutical; Cytidine; Drug Design; Drug Evaluation, Preclinical; Hepacivirus; Hepatitis C; Humans; Models, Chemical; Prodrugs; Replicon; Technology, Pharmaceutical; Virus Replication | 2009 |
Chemical stability of 4'-azidocytidine and its prodrug balapiravir.
Topics: Antiviral Agents; Azides; Chemical Phenomena; Cytidine; Drug Stability; Hydrogen-Ion Concentration; Nucleosides; Prodrugs | 2010 |
Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir.
Topics: Animals; Antiviral Agents; Cytidine; Cytokines; Dengue; Dengue Virus; Female; Humans; Leukocytes, Mononuclear; Mice; Nucleosides; Prodrugs | 2014 |
Quantification of 2'-deoxy-2'-β-fluoro-4'-azidocytidine in rat and dog plasma using liquid chromatography-quadrupole time-of-flight and liquid chromatography-triple quadrupole mass spectrometry: Application to bioavailability and pharmacokinetic studies.
Topics: Animals; Biological Availability; Chromatography, High Pressure Liquid; Cytidine; Deoxycytidine; Dogs; Female; Lamivudine; Male; Mass Spectrometry; Plasma; Rats; Rats, Sprague-Dawley; Reference Standards | 2014 |
Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs.
Topics: Adenosine; Amides; Antiviral Agents; Cell Line; Cytidine; DNA-Directed RNA Polymerases; Guanosine Monophosphate; Humans; Inhibitory Concentration 50; Mitochondria; Mitochondrial Proteins; Nucleosides; Prodrugs; Protein Biosynthesis; Pyrazines; Ribonucleosides; RNA; RNA, Mitochondrial; Sofosbuvir; Structure-Activity Relationship; Transcription Initiation Site; Transcription, Genetic | 2017 |
4'-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency.
Topics: Antiviral Agents; Cell Line; Cytidine; Humans; Microbial Sensitivity Tests; Paramyxoviridae | 2017 |
Susceptibility of paramyxoviruses and filoviruses to inhibition by 2'-monofluoro- and 2'-difluoro-4'-azidocytidine analogs.
Topics: Antiviral Agents; Cytidine; Ebolavirus; Henipavirus; Marburgvirus; Microbial Sensitivity Tests | 2018 |